临床实践指南对良好循证临床药学实践的指导作用

孙增先,,刘乃丰,*

中国药学杂志 ›› 2014, Vol. 49 ›› Issue (21) : 1950-1956.

PDF(1681 KB)
中国药学杂志
PDF(1681 KB)
中国药学杂志 ›› 2014, Vol. 49 ›› Issue (21) : 1950-1956. DOI: 10.11669/cpj.2014.21.020
药物与临床

临床实践指南对良好循证临床药学实践的指导作用

  • 孙增先1,2,刘乃丰1,3*
作者信息 +

The Guiding Role of Clinical Practice Guidelines in Good Evidence-Based Clinical Pharmacy Practice

  • SUN Zeng-xian1,2, LIU Nai-feng1,3*
Author information +
文章历史 +

摘要

目的 阐述临床实践指南(CPGs)对良好循证临床药学实践(EBCPP)的促进和指导作用,促进临床合理使用药物。方法 在查阅近年最新循证临床实践指南的基础上,从生物标志物指导循指南药物治疗、新的循证药物治疗学、药品不良反应(ADR)防治以及临床用药评价4个方面阐述临床实践指南对循证临床药学实践的指导作用。结果与结论 临床药师应主动跟踪最新循证临床实践指南,遵循并坚持循指南药物治疗策略,将最新循证药物治疗学成果运用于循证临床药学实践,提供满足于临床、患者需求的临床药学服务,改善患者预后和生活质量,确保医疗安全,提高医疗质量。

Abstract

OBJECTIVE To elaborate the promotion and guidance of clinical practice guidelines to good practice of evidence-based clinical pharmacy, and the promotion to scientifical and rational use of drugs. METHODS To summarise on four aspects: the biomarker guided guideline-based drug therapy, the new evidence-based pharmacotherapeutics, the prevention of adverse reactions, and the clinical drug evaluation, based on the latest evidence-based clinical practice guidelines. RESULTS AND CONCLUSION In order to provide clinical pharmacy services to meet the needs of clinic and patients, improve the prognosis and quality of life of patients, ensure medical safety and improve quality of medical care, clinical pharmacists should take the initiative to track the latest evidence-based clinical practice guidelines, follow and adhere guideline-based drug therapy strategy, and put the latest evidence-based pharmacotherapeutical achievement into practice.

关键词

临床实践指南 / 循证临床药学实践 / 循指南药物治疗 / 糖化血红蛋白 / 肿瘤生物标志物 / 华法林 / β受体阻滞剂

Key words

clinical practice guidelines / evidence-based clinical pharmacy practice / guideline-based drug therapy / glycosylated hemoglobin / tumor biomarker / warfarin / beta-blockers

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
孙增先,,刘乃丰,*. 临床实践指南对良好循证临床药学实践的指导作用[J]. 中国药学杂志, 2014, 49(21): 1950-1956 https://doi.org/10.11669/cpj.2014.21.020
SUN Zeng-xian,, LIU Nai-feng,*. The Guiding Role of Clinical Practice Guidelines in Good Evidence-Based Clinical Pharmacy Practice[J]. Chinese Pharmaceutical Journal, 2014, 49(21): 1950-1956 https://doi.org/10.11669/cpj.2014.21.020
中图分类号： R969.3   

参考文献

[1] SUN Z X, LIU N F. Evidence-based clinical pharmacy practice[J]. Chin J New Drug Clin Rem(中国新药与临床杂志),2014,33(9):639-645.[2] Chinese Diabetes Society. Guideline of prevention and treatment for Chinese with type 2 diabetes (version 2010)[J]. Chin J Diabetes(中国糖尿病杂志), 2012, 20(1): 1-36.[3] American diabetes association. Standards of medical care in diabetes 2010[J]. Diabetes Care, 2010, 33(suppl 1): 11-61.[4] WS 397-2012, Criteria for the screening and diagnosis of diabetes mellitus(糖尿病筛查和诊断)[S]. 2012: 1-7.[5] Chinese Society of Endocrinology. Expert consensus of HbA1C control target for Chinese adult with type 2 diabetes[J]. Chin J Endocrinol Metab (中华内分泌代谢杂志), 2011, 27(5): 371-374.[6] American diabetes association. Standards of medical care in diabetes 2013[J]. Diabetes Care, 2013, 36(suppl 1): 11-66 .[7] GARBER A J, ABRAHAMSON M J, BARZILAY J I, et al. American association of clinical endocrinologists′ comprehensive diabetes management algorithm 2013 consensus statement[J]. Endocr Pract, 2013,19 (suppl 2): 1-48.[8] ETTINGER D S, WOOD D E, AKERLEY W, et al. NCCN Non-small cell lung cancer guidelines (version 3. 2014)[EB/OL]. [2013-11-20], http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf (nccn 2014).[9] ETTINGER D S, AKERLEY W, BORGHAEI H, et al. NCCN Non-small cell lung cancer guidelines (chinese)(version 1. 2011)[J/OL]. http://www.nccnchina.org.cn/nccn-guidelines-china.aspx.[10] GUYATT G H, AKL E A, CROWTHER M, et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines[J]. Chest, 2012, 141(2 suppl): 7-47.[11] CAMM A J, LIP G Y, D E CATERINA R, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation[J]. Eur Heart J, 2012, 33(21): 2719-2747 .[12] ANDERSON J L, HALPERIN J L, ALBERT N M, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations)[J]. J Am Coll Cardiol, 2013, 61(18): 1935-1944.[13] VAHANIAN A, ALFIERI O, ANDREOTTI F, et al. Guidelines on the management of valvular heart disease (version 2012)[J]. Eur Heart J, 2012, 33(19): 2451-2496.[14] Expert Committee on Hypertension of Chinese Medical Doctor Association (CMDA), FENG Y Q, LI Y, et al. Expert guidelines for β receptor blockers in hypertension [J]. Chin J Front Med Sci (Electronic Version) (中国医学前沿杂志:电子版), 2013, 5(4): 58-66.[15] MANCIA G, FAGARD R, NARKIEWICZ K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension[J]. J Hypertens, 2013, 31(7): 1281-1357.[16] YANCY C W, JESSUP M, BOZKURT B, et al. 2013 ACCF/AHA Guideline for the management of heart failure[J]. J Am Coll Cardiol, 2013, 62(16): 147-239 .[17] MCMURRAY J J, ADAMOPOULOS S, ANKER S D, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012[J]. Eur Heart J, 2012, 33(14): 1787-1847.[18] JNEID H, ANDERSON J L, WRIGHT R S, et al. 2012 ACCF/AHA Focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction[J]. J Am Coll Cardiol, 2013, 61(23): 179-347.[19] HAMM C W, BASSAND J P, AGEWALL S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J, 2011, 32(23): 2999-3054.[20] O′GARA P T, KUSHNER F G, ASCHEIM D D, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction[J]. J Am Coll Cardiol, 2013, 61(4): 78-140.[21] STEG P G, JAMES S K, ATAR D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Eur Heart J, 2012, 33(20): 2569-2619.[22] CAMM A J, KIRCHHOF P, LIP G Y, et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (ESC)[J]. Eur Heart J, 2010, 31(19): 2369-2429.[23] Chinese Society of Cardiology, the Committee of Cardio-Cerebral-Vascular Diseases of Gerontological Society of China (GSC), Chinese Heart Rhythm Society (CHRS), et al. Chinese expert consensus of anticoagulant therapy in atrial fibrillation[J]. Chin J Intern Med (中华内科杂志), 2012, 51(11): 916-921.[24] Writing group of Chinese experts proposal for diagnosis and treatment in the elderly auricular fibrillation, Geriatrics Branch of Chinese Medical Association, Editorial Board of Chinese Journal of Geriatrics. Diagnosis and treatment in the elderly auricular fibrillation: Chinese expert proposal (2011)[J]. Chin J Geriatr (中华老年医学杂志), 2011, 30(11): 894-908.[25] YANG J G. Chinese expert consensus of diagnosis and pharmacotherapy of atrial fibrillation [J]. Prev Treat Cardio Cereb Vasc Dis(心脑血管病防治), 2008, 8(4): 215-222.[26] TAN X P, YAN P K, WANG Y, et al. Evaluation of the application of antibiotics for MRSA infection in our hospital based on guideline[J]. J China Pharm(中国药房), 2013, 24(22): 2054-2056.[27] LIU C, BAYER A, COSGROVE S E, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children[J]. Clin Infect Dis, 2011, 52(3):18-55.[28] XU J H, ZHU W Y. Analysis of chemotherapeutic regimens and the use of adjuvant chemotherapeutic drugs in lung adenocarcinama[J]. J China Pharm(中国药房), 2013, 24(22): 2038-2040.[29] ETTINGER D S, BERGER M J, ARMSTRONG D K, et al. NCCN Antiemesis guidelines (version 1.2014). [2013-11-20], http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf.[30] HEIDBUCHEL H, VERHAMME P, ALINGS M, et al. European heart rhythm association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace, 2013, 15(5): 625-651.[31] DOMINGUEZ-RODRIGUEZ A, BLANCO-PALACIOS G, ABREU-GONZALEZ P. Increased heart rate and atherosclerosis: Potential implications of ivabradine therapy[J]. World J Cardiol, 2011,3(4): 101-104.[32] RICCIONI G. Ivabradine: From molecular basis to clinical effectiveness[J]. Adv Ther, 2010,27(3): 160-167.[33] DUFFULL S B, AARONS L. Development of a sequential linked pharmacokinetic and pharmacodynamic simulation model for ivabradine in healthy volunteers[J]. Eur J Pharm Sci, 2000, 10(4): 275-284.[34] WANG J X, LI H W. Progress in applications of digoxin about clinical benefits and risks[J]. Chin Gen Pract(中国全科医学), 2013, 16(6A): 1927-1929.[35] LU Y X. Thoughts about the 2012 european guidelines for heart failure [J]. Chin J Front Med Sci(Electronic Version)(中国医学前沿杂志:电子版), 2013, 5(4): 67-70.[36] Chinese Society of Cardiology, Editorial Board of Chinese Journal of Cardiology. Guidelines for the diagnosis and treatment of non-ST segment elevation acute coronary syndrome[J]. Chin J Cardiol (中华心血管病杂志), 2012, 40(5): 353-367.
PDF(1681 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉